Janssen Therapeutics, a division of health care products giant Johnson & Johnson (JNJ), won FDA approval for Sirturo, its treatment for drug-resistant tuberculosis. Sirturo will be the 1st new drug to treat TB in 40 years, the company said. The disease has been treated with generic antibiotics. The FDA designates the TB mutation it treats, multidrug-resistant TB, an "orphan disease" that affects a small number of patients. Cowen estimates peak Sirturo yearly sales of about $300 mil. Shares rose 0.9% to 70.10.